Analyzing Arbutus Biopharma (NASDAQ:ABUS) & Werewolf Therapeutics (NASDAQ:HOWL)

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) and Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Volatility & Risk

Werewolf Therapeutics has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500. Comparatively, Arbutus Biopharma has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500.

Institutional & Insider Ownership

64.8% of Werewolf Therapeutics shares are owned by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are owned by institutional investors. 23.6% of Werewolf Therapeutics shares are owned by insiders. Comparatively, 19.9% of Arbutus Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Werewolf Therapeutics and Arbutus Biopharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Werewolf Therapeutics N/A -166.99% -59.88%
Arbutus Biopharma 121.17% 129.12% 89.26%

Valuation and Earnings

This table compares Werewolf Therapeutics and Arbutus Biopharma”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Werewolf Therapeutics $1.88 million 25.34 -$60.82 million ($0.76) -1.29
Arbutus Biopharma $14.08 million 44.53 -$33.50 million $0.79 5.18

Arbutus Biopharma has higher revenue and earnings than Werewolf Therapeutics. Werewolf Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for Werewolf Therapeutics and Arbutus Biopharma, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Werewolf Therapeutics 1 4 2 0 2.14
Arbutus Biopharma 0 1 0 0 2.00

Werewolf Therapeutics presently has a consensus price target of $4.00, suggesting a potential upside of 308.04%. Given Werewolf Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Werewolf Therapeutics is more favorable than Arbutus Biopharma.

Summary

Arbutus Biopharma beats Werewolf Therapeutics on 9 of the 14 factors compared between the two stocks.

About Werewolf Therapeutics

(Get Free Report)

Werewolf Therapeutics, Inc. is a clinical-stage biotechnology company developing medicines for cancer. Its research focuses on cytokines, immune-signaling proteins that can stimulate the body’s immune response against tumors. The company’s INDUKINE platform is designed to keep cytokine therapies inactive until they reach the tumor environment, with the goal of limiting effects on healthy tissue. Its investigational programs include WTX-124, based on interleukin-2, and WTX-330, based on interleukin-12.

About Arbutus Biopharma

(Get Free Report)

Arbutus Biopharma is a clinical-stage biopharmaceutical company focused on developing treatments for chronic hepatitis B virus (HBV) infection. Its research programs include RNA interference (RNAi) therapies, immune-based treatments and capsid assembly inhibitors, which target different aspects of the virus and the body’s response to infection. The company’s investigational portfolio includes imdusiran, an RNAi therapeutic designed to reduce hepatitis B surface antigen, as well as other HBV drug candidates at various stages of development.

Receive News & Ratings for Werewolf Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Werewolf Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.